jump to content jump to footer

Early Detection of Treatment Response in Lung Cancer Using Delta-Radiomics Features

The study conducted by Heidelberg University Hospital investigates the use of diffusion-weighted MRI (DWI) to predict early treatment outcomes in patients with advanced lung adenocarcinoma. The researchers analyzed changes in radiomic features derived from ADC (Apparent Diffusion Coefficient) maps in 144 patients who were treated with either tyrosine kinase inhibitors (TKI) or platinum-based chemotherapy (PBC).

The study found that radiomic features, known as delta-radiomics features (DRFs), were able to predict treatment success and progression-free survival (PFS) as early as 14 days after the start of treatment.

These features enabled the distinction between patients with likely better and worse treatment outcomes.

The use of DWI-based radiomics shows promising potential for early decision-making in lung cancer treatment and could allow physicians to adjust therapies more quickly.

This approach offers a non-invasive, radiation-free alternative for early assessment of treatment success in lung cancer.

Read more about the study here.

Research with mint mintLesion Clinical Research MRI Personalized Therapy Therapy Response Assessment Radiomics Texture Analysis

Related Resources

mint Lesion usage during a clinical trial read, featuring the TGRM export tool.
Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer

For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…

Participants at the RECIST and Beyond workshop in Cologne during hands-on training with mint Lesion for structured tumor response assessment.
The two-day “RECIST and Beyond” workshop at radCIO Cologne offered intensive hands-on training on RECIST, iRECIST, mRECIST and LI-RADS, with real-case reporting performed directly in mint Lesion.
Successful “RECIST and Beyond” Workshop in Cologne: Advancing Precision in Oncologic Imaging

How can complex tumor findings be assessed accurately, reproducibly, and in line with clinical guidelines?

Screenshot of the mint Lesion interface showing RANO 2.0 configuration, tumor burden calculations, and structured neuro-oncology assessment tools.
mint Lesion fully supports RANO 2.0 implementation with configurable parameters, automated tumor burden calculations, and structured workflows for neuro-oncology clinical trials.
Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion

Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…